Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 33%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Progyny is a rapidly growing fertility benefits company with a strong focus on compliance and a unique product, ProgynyRx, which sets them apart in the market. Despite competition and potential challenges, the company remains disciplined and optimistic in its growth potential, making it an attractive investment opportunity for analysts.

Bears say

Progyny is facing headwinds due to slowing growth in the 50K+ client category and potential divestments. Furthermore, there are concerns over potential competition from health plans and regulatory risk. Their seasonal revenue patterns may also lead to volatility in earnings. However, Progyny's focus on healthcare integration, specialization in the growing fertility market, and long-term strong financial performance suggest potential for future growth and profitability.

Progyny (PGNY) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 33% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 9 analysts, Progyny (PGNY) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.